간문부 담관암의 최근 치료 성적 = Special Review : Current treatment outcome of hilar cholangiocarcinoma

다국어 초록 (Multilingual Abstract)

Cholangiocarcinoma (CC) is one of the most lethal cancers defying long-term control of disease. Hilar cholangiocarcinoma (Klatskin tumor) which occur at the confluence of right and left hepatic ducts are getting special attention for these tumors due to difficult management. Surgical treatment of hilar cholangiocarcinoma remains difficult and most of patients are diagnosed when unresectable. The 5-year survival rate after curative resection was 20~40% with median survival of 12~16 months. In those patients with unresectable hilar CC, liver failure and recurrent sepsis secondary to biliary obstruction occupy substantial proportion of cause of death. For most of these patients endoscopic or percutaneous biliary drainage provides effective palliation. Palliative chemotherapy and radiation therapy either alone or in combination have been relatively ineffective for unresectable cholangiocarcinoma. A photodynamic therapy is an emerging palliative treatment that seems to provide pain relief, improve biliary patency and increase survival. In addition to these options, newly developed target therapies are promising, but still experimental treatment. Liver transplantation in combination with neoadjuvant chemoradiation therapy seems to be an option for a highly selected group of patients. The development of new therapeutic options and multimodal promising combinations of the palliative therapeutic options is expected to improve the health-related quality of life and prolong the overall survival. (Korean J Med 79:623-629, 2010)

참고문헌 (Reference)

1 천영국, "진행성 간문부담관암 환자에서 내시경 담도배액술 단독 치료와 경피경간 담도배액술을 병행한 담도경하 광역동치료의 생존율의 비교 연구" 대한소화기학회 44 (44): 280-287, 2004

2 이승규, "단일 센터에서 시행한 간문부담관암의 수술적 절제후 생존율에 영향을 미치는 인자에 대한 분석" 한국간담췌외과학회 11 (11): 32-39, 2007

3 Golfieri R, "Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy" 20 : 757-760, 2006

4 Thongprasert S, "Therole of chemotherapy in cholangiocarcinoma" 16 (16): ii93-ii96, 2005

5 Forsmo HM, "Survival and an overview of decision-making in patients with cholangiocarcinoma" 7 : 412-417, 2008

6 Ortner ME, "Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study" 125 : 1355-1363, 2003

7 Jarnagin WR, "Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma" 234 : 507-517, 2001

8 Zervos EE, "Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach" 190 : 810-815, 2005

9 Kim S, "Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer" 54 : 414-419, 2002

10 Gerhards MF, "Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma" 27 : 173-179, 2003

11 Ishii H, "Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting" 51 : 954-957, 2004

12 Smith AC, "Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction" 344 : 1655-1660, 1994

13 Todoroki T, "Radical resection of hilar bile duct carcinoma and predictors of survival" 87 : 306-313, 2000

14 Stein DE, "Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy" 28 : 21-23, 2005

15 Berr F, "Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival" 31 : 291-298, 2000

16 Patt YZ, "Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer" 14 : 2311-2315, 1996

17 Kubicka S, "Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas" 48 : 783-789, 2001

18 Hong YS, "Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer" 60 : 321-328, 2007

19 Zhu AX, "Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) and oxaliplatin (OX)" 27 (27): 4578-, 2009

20 Kuvshinoff BW, "Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy" 82 : 1522-1525, 1995

21 Nehls O, "Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial" 87 : 702-704, 2002

22 Chang WH, "Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage" 47 : 354-362, 1998

23 Wiedmann M, "Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study" 97 : 2783-2790, 2003

24 Jongha Park, "Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study" 거트앤리버 발행위원회 3 (3): 298-305, 2009

25 Ohnishi H, "Mine T. External radiotherapy for biliary decompression of hilar cholangiocarcinoma" 42 : 265-268, 1995

26 Cameron JL, "Management of proximal cholangio carcinomas by surgical resection and radiotherapy" 159 : 91-98, 1990

27 Rea DJ, "Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients" 139 : 514-523, 2004

28 Itoh H, "Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder" 50 : 2231-2242, 2005

29 Devière J, "Long-term follow-up of patients with hilar malignant Stricture treated by endoscopic internal biliary drainage" 34 : 95-101, 1988

30 Serafini FM, "Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy" 67 : 839-844, 2001

31 Rea DJ, "Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma" 242 : 451-458, 2005

32 Kaiser GM, "Liver transplantation for hilar cholangiocarcinoma: a German survey" 40 : 3191-3193, 2008

33 Meyer CG, "Liver transplantation for cholangiocarcinoma: results in 207 patiens" 69 : 1633-1637, 2000

34 Gruenberger B, "K-ras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine-oxaliplatin (GEMOX): a single center phase II study" 27 (27): 4586-, 2009

35 Takada T, "Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?: a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma" 95 : 1685-1695, 2002

36 Takamura A, "Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma" 57 : 1357-1365, 2003

37 Kosuge T, "Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection" 230 : 663-671, 1999

38 Ebata T, "Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases" 238 : 720-727, 2003

39 Murakami Y, "Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma" 13 : 1470-1479, 2009

40 André T, "Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GER OR study" 15 : 1339-1343, 2004

41 Kondo S, "Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospeilar cstudy" 240 : 95-101, 2004

42 Choi CW, "Effects of 5- fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas" 23 : 425-428, 2000

43 Sagawa N, "Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma" 35 : 548-552, 2005

44 Ducreux M, "Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin" 9 : 653-656, 1998

45 Anderson CD, "Diagnosis and treatment of cholangiocarcinoma" 9 : 43-57, 2004

46 Nelson JW, "Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma" 73 : 148-153, 2009

47 Knox JJ, "Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial" 23 : 2332-2338, 2005

48 Lee GW, "Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma" 29 : 127-131, 2006

49 Jang JY, "Clinical outcome of surgical treatment for Klatskin tumor" 14 : 130-134, 2009

50 Nakeeb A, "Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors" 224 : 463-475, 1996

51 Lai EC, "Choice of palliation for malignant hilar biliary obstruction" 163 : 208-212, 1992

52 Eckel F, "Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials" 96 : 896-902, 2007

53 Todoroki T, "Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery" 47 : 644-649, 2000

54 Figueras J, "Changing strategies in diagnosis and management of hilar cholangiocarcinoma" 6 : 786-794, 2000

55 Todoroki T, "Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma" 46 : 581-587, 2000

56 Aljiffry M, "Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009" 15 : 4240-4262, 2009

57 Hughes MA, "Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct" 68 : 178-182, 2007

58 Klatskin G, "Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: an unusual tumor with distinctive clinical and pathological features" 38 : 241-256, 1965